Entero Therapeutics Inc ENTO

Healthcare Biotechnology

Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

NDAQ:ENTO - Post by User

Entero Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Oct 31, 2022 1:20pm

126 Views

Post# 35060573

FWBI ...Sure does seem strange how this can churn 11.7 mil..

shares and be down 3 cents.... I mean holy cr*p.....there was only 1.4 million shares p/s post RS then they printed some cheap paper via a P.O...that was 3.4 million shares at $1.75...so all totaled theres a grand total of just under 5 million shares o/s

Not trying to pump my book....but all I can say is ..... I will buy this til I'm blue in the face

This is now my last post on this .... U all now where I stand and what I am going to do

GLTA

Cheers !

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security